No Data
No Data
No Data
No Data
No Data
Express News | Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Moomoo 24/7Apr 15 11:00 ET
Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning
TipRanksApr 11 15:05 ET
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company or
GlobeNewswireApr 10 07:03 ET
Express News | Unicycive Therapeutics Shares Are Trading Higher After Piper Sandler Initiated Coverage on the Stock With an Overweight Rating and a Price Target of $9
Moomoo 24/7Apr 4 07:53 ET
Unicycive Therapeutics Initiated at Overweight by Piper Sandler
Unicycive Therapeutics Initiated at Overweight by Piper Sandler
Dow JonesApr 4 07:13 ET
Express News | Piper Sandler Initiates Coverage On Unicycive Therapeutics With Overweight Rating, Announces Price Target of $9
Moomoo 24/7Apr 4 07:03 ET
No Data
No Data